Combining EBRT and HDR-BT in high-risk prostate cancer: an effective and safe experience

被引：0
|
作者：
Candini, D. [1 ]
Lopez-Campos, F. [1 ]
Munoz, T. [1 ]
Martin, M. [1 ]
Vallejo, C. [1 ]
Hervas, A. [1 ]
机构：
[1] Hosp Ramon & Cajal, Radiat Oncol, Madrid, Spain
来源：
RADIOTHERAPY AND ONCOLOGY | 2018年 / 127卷
关键词：
D O I：
10.1016/S0167-8140(18)31847-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP-1538
引用
收藏
页码：S831 / S831
页数：1
相关论文
共 50 条
  • [41] PSA-kinetic after percutaneous radiotherapy (EBRT), temporary interstitial bracytherapy (HDR-BT) as boost to percutaneous radiotherapy as well as permanent interstitial brachytherapy (LDR-BT) as monotherapy in prostate carcinoma
    Pinkawa, M.
    Piroth, M. D.
    Holy, R.
    Klotz, J.
    Borchers, H.
    Eble, M. J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 : 34 - 34
  • [42] Combining hormones with radiation benefits high-risk prostate cancer patients
    不详
    ONCOLOGY-NEW YORK, 2005, 19 (10): : 1389 - 1390
  • [43] The radiosensitivity index predicts benefit from HDR brachytherapy in high-risk prostate cancer
    Thiruthaneeswaran, N.
    Bibby, B. A. S.
    Pereira, R.
    More, E.
    Denley, H.
    Henry, A.
    Wylie, J.
    Hoskin, P.
    Bristow, R.
    Choudhury, A.
    West, C.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S1086 - S1087
  • [44] HDR Brachytherapy in the Management of High-Risk Prostate Cancer (Vol 2012, 980841, 2012)
    Masson, Susan
    Persad, Raj
    Bahl, Amit
    ADVANCES IN UROLOGY, 2016, 2016
  • [45] Avoiding EBRT for those without high-risk endometrial cancer
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2011, 8 (6) : 316 - 316
  • [46] Biochemical control in intermediate- and high-risk prostate cancer after EBRT with and without brachytherapy boost
    Moll, Matthias
    Magrowski, Lukasz
    Mittlboeck, Martina
    Heinzl, Harald
    Kirisits, Christian
    Ciepal, Jakub
    Masri, Oliwia
    Heilemann, Gerd
    Stando, Rafal
    Krzysztofiak, Tomasz
    Depowska, Gabriela
    d'Amico, Andrea
    Techmanski, Tomasz
    Kozub, Anna
    Majewski, Wojciech
    Suwinski, Rafal
    Wojcieszek, Piotr
    Sadowski, Jacek
    Widder, Joachim
    Goldner, Gregor
    Miszczyk, Marcin
    STRAHLENTHERAPIE UND ONKOLOGIE, 2025, 201 (01) : 11 - 19
  • [47] Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer
    Galalae, RM
    Martinez, A
    Mate, T
    Mitchell, C
    Edmundson, G
    Nuernberg, N
    Eulau, S
    Gustafson, G
    Gribble, M
    Kovács, G
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (04): : 1048 - 1055
  • [48] Detrimental outcome of short term hormonal treatment and high dose radiation therapy (EBRT plus HDR) when compared to EBRT plus HDR alone for high risk prostate patients
    Martinez, A
    Vargas, C
    Demanes, J
    Galalae, R
    Bertermann, H
    Rodriguez, R
    Gonzalez, J
    Altieri, G
    Gustafson, G
    Kestin, L
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S469 - S469
  • [49] RELATIONSHIP BETWEEN TREATMENT PLAN PARAMETERS AND PARTICULAR PROGNOSTIC FACTORS IN PROSTATE CANCER TREATED WITH HIGH-DOSE-RATE BRACHYTHERAPY (HDR-BT) AS A BOOST.
    Chichel, A.
    Kanikowski, M.
    Skowronek, J.
    Dymnicka, M.
    Piotrowski, T.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S339 - S339
  • [50] Palliative combined treatment by high-dose-rate brachytherapy (HDR-BT) and stents in patients with esophageal cancer.
    Kanikowski, M.
    Skowronek, J.
    Clichel, A.
    Kubaszewska, M.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S269 - S269
12345